Scientists test Double-Drug attack on inherited breast cancer
NCT ID NCT03641755
Summary
This early-stage study is testing the safety and effectiveness of combining two drugs, olaparib and sapacitabine, for people with advanced breast cancer linked to a BRCA gene mutation. The main goals are to find the safest dose and see if the combination can shrink tumors. It is a small study for patients whose cancer has continued to grow despite other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Broad Institute of MIT
Cambridge, Massachusetts, 02142, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.